Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学FGFR Inhibitor Therapy

Funda Meric-Bernstam

MD

🏢MD Anderson Cancer Center🌐USA

Chair Department of Investigational Cancer Therapeutics

100
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Funda Meric-Bernstam leads the phase I program at MD Anderson and is a leader in precision oncology trials. She has contributed to pivotal FGFR inhibitor studies across tumor types. Her work has advanced molecularly matched therapy in early phase drug development. She is among the most influential drug development leaders in oncology.

Share:

🧪Research Fields 研究领域

phase I trials
FGFR inhibitors
precision oncology
breast cancer
targeted therapy

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 Funda Meric-Bernstam 的研究动态

Follow Funda Meric-Bernstam's research updates

留下邮箱,当我们发布与 Funda Meric-Bernstam(MD Anderson Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment